Pasithea therapeutics signs cmc development and manufacturing agreement for the production of pas-004

-- plans to initiate a phase 1 clinical trial in the u.s. for neurofibromatosis type 1 (nf1) in 2h 2023 -- miami beach, fla., jan. 18, 2023 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (cns) disorders, today announced its contract with wuxi sta, a subsidiary of wuxi apptec, to manufacture the active pharmaceutical ingredient (“api”) for pasithea's macrocyclic, next-generation mek inhibitor, pas-004 (formerly cip-137401).
KTTA Ratings Summary
KTTA Quant Ranking